A Retrospective Study Analysing Impact of Immune Checkpoint Inhibitor Therapy on Development of Pulmonary Arterial Hypertension and Right Ventricular Dysfunction
Latest Information Update: 03 Jul 2020
At a glance
- Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer; Thoracic neoplasms
- Focus Adverse reactions
Most Recent Events
- 03 Jul 2020 New trial record
- 20 May 2020 Results presented at the 116th International Conference of the American Thoracic Society